BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:High-throughput Cancer Cell line Screens: Linking Drug Response to
  Molecular Signatures - Dr Ultan McDermott\, Cancer Genome Project\, Wellc
 ome Trust Sanger Institute
DTSTART:20100209T120000Z
DTEND:20100209T130000Z
UID:TALK19420@talks.cam.ac.uk
CONTACT:Mala Jayasundera
DESCRIPTION:Selective kinase inhibitors have emerged as an important class
  of cancer therapeutics. The clinical success of drugs such as imatinib\, 
 erlotinib\, and lapatinib\, together with findings demonstrating the impor
 tant relationship between specific tumor genotypes and clinical response t
 o these agents\, also has brought to the forefront the concept of "persona
 lized cancer medicine." The potential broader significance of this relatio
 nship has been further highlighted in preclinical studies using tumor-deri
 ved cell lines as a model system that can faithfully recapitulate the asso
 ciation of specific genotypes with drug sensitivity\, suggesting the utili
 ty of cancer cell lines to identify novel candidate biomarkers for predict
 ing clinically responsive patient subsets for newly developed anticancer a
 gents. The case of the anaplastic lymphoma kinase (ALK) nicely exemplifies
  this\, and cell line profiling has revealed that ALK mutations present in
  a subset of anaplastic large cell lymphomas (ALCLs)\, non-small cell lung
  cancers (NSCLCs)\, and neuroblastomas appear to sensitize cancer cells to
  treatment with selective ALK kinase inhibitors. Such findings suggest tha
 t genotype-based stratification of cancer patients for treatment with sele
 ctive kinase inhibitors\, even across multiple diseases of distinct tissue
  origin\, may be essential for maximizing their clinical benefit.
LOCATION:CRI Lecture Theatre
END:VEVENT
END:VCALENDAR